Navigation Links
RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments
Date:1/13/2009

ence Interval: 50 - 91 days), with 29.6% of patients estimated to still be progression-free at four months. Median overall survival was not attained at the time of evaluation.

The most commonly reported adverse events (all grades; >10% patients) in the study included, stomatitis, anorexia, fatigue, rash, nausea, edema peripheral, thrombocytopenia, diarrhea, pruritus, anemia, dysgeusia, vomiting, pyrexia, pneumonitis, constipation and insomnia. Serious adverse events (grade 3 or 4; >3% of patients) included anemia, hyponatremia, raised liver function, fatigue, stomatitis, anorexia, hyperglycemia, hypophosphatemia, ileus and lymphopenia.

About RAD001

RAD001, an oral once-daily inhibitor of mTOR, is an investigational drug being studied in multiple tumor types. In cancer cells, RAD001 provides daily inhibition of mTOR, a protein that acts as a central regulator of tumor cell division, cell metabolism and blood vessel growth.

RAD001 is being studied in multiple cancer types including advanced kidney, breast and neuroendocrine tumors and lymphoma. Currently, RAD001 is under regulatory review in the US and Europe for the treatment of advanced renal cell carcinoma.

The safety and efficacy profile of RAD001 has not yet been established in oncology and there is no guarantee that RAD001 will become commercially available for oncology indications. The active ingredient in RAD001 is everolimus, which is available in different dosage strengths under the trade name Certican(R) for the prevention of organ rejection in heart and kidney transplant recipients. Certican was first approved in the EU in 2003. Certican is not approved in the US.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "promising," "will," "potential," "may," "committed," "exploring," "believed," "e
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
2. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
3. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
4. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
5. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
6. Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
7. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
10. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Integrated Silicon Solution, Inc. (Nasdaq: ... IC solutions, today announced that it will host its ... 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) to ... third quarter ended June 30, 2014. To ... 6:50 a.m. Pacific time on July 24, 2014.  The ...
(Date:7/10/2014)... --  Ventana Medical Systems, Inc.  (Ventana), a member of ... an agreement with Merck KGaA, Darmstadt, Germany ... the United States and ... division on the development and commercialization of a companion ... diagnostic assays. In alignment with Merck KGaA,s strategic approach ...
(Date:1/15/2014)... 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) today announced ... 2013, compared to sales of $2,202,000 for the prior year ... quarter has also shown growth over the preceding quarter,s sales, ... this fiscal year. Markets that experienced sales increases over the ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... YORK, May 11, 2011 Reportlinker.com ... report is available in its catalogue: ... Trends 2011 – Generics Market Overview: ... generic uptake despite tougher market conditions ...
... TOKYO, May 11, 2011 Daiichi Sankyo announced that ... (PLX4032/RG7204) for the treatment of metastatic melanoma to the ... Medicines Agency (EMA).  Additionally, a pre-marketing application for approval ... the U.S.; the test also will be registered in ...
Cached Medicine Technology:Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions 2Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions 3Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions 4Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions 5Vemurafenib New Drug Application Submitted to FDA for Melanoma 2Vemurafenib New Drug Application Submitted to FDA for Melanoma 3Vemurafenib New Drug Application Submitted to FDA for Melanoma 4
(Date:7/13/2014)... 13, 2014 The North American water storage ... 2013 to $5,450 million by 2018, at a CAGR of ... is expanding at a rapid pace in North America. The ... laws on water & wastewater storage and collection, and the ... market is expanding at a healthy rate in Canada, and ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 The ... Copper, Molybdenum, Iron), Form (Chelated & Non Chelated), ... Geography - Global Trends and Forecast to 2018” ... with an analysis and forecasting of the global ... identifies the driving and restraining factors for the ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Fuel additives ... as gasoline, diesel, jet fuel, kerosene, and so on, ... also responsible for reducing the corrosion effects caused by ... when added to any fuel, provide economies of scale ... these escalate the overall cost of the fuel products. ...
(Date:7/13/2014)... 2014 MarketsandMarkets recently conducted a ... 3D Scanning; 3D rendering; Layout and Animation; Image ... - 2018)”, which analyzes and studies the major ... Western Europe, Eastern Europe, Middle East and Africa, ... the competitive landscape of the 3D imaging market, ...
(Date:7/13/2014)... Serena Gordon HealthDay ... A new type of sensor for people with diabetes ... using saliva instead of blood, researchers report. Scientists at ... tested it using artificial saliva. It uses light, metal and ... sugar. "Everybody knows that diabetics have to prick their ...
Breaking Medicine News(10 mins):Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3
... joint researchers continue to seek better ways to diagnose ... following total joint arthroplasty. Their latest research shows ... tract infections, can also have a role in rapid ... previous work conducted by Javad Parvizi, MD, FRCS, director ...
... HealthDay Reporter , MONDAY, Feb. 6 (HealthDay News) -- ... like those found on the tongue -- that can "taste" ... foods and beverages. Nutrition experts have warned that Americans take ... bolster their concerns. In lab studies of pancreas cells ...
... , MONDAY, Feb. 6 (HealthDay News) -- Treatment with ... a slightly increased risk of death, a new analysis ... be taken into account by doctors and patients, according ... investigators analyzed the findings of 10 clinical trials that ...
... A recent discovery by Van Andel Research Institute (VARI) ... drug therapies for glioblastoma the most common and ... study, published in January in the Proceedings of ... characterized by cell signaling activation and gene amplification for ...
... for 30 years, has finally provided convincing evidence that ... symptoms of painful menstrual periods reports scientists from the ... published in Europes leading reproductive medicine journal Human ... have suggested that the combined oral contraceptive pill could ...
... Infectious disease has joined poaching and habitat loss as ... apes as they have become restricted to ever-smaller populations. ... our closest living relatives from ecological extinction are largely ... major threats and find innovative solutions. In response ...
Cached Medicine News:Health News:Rothman Institute at Jefferson research suggests use of LE strips to diagnose PJI 2Health News:Pancreas May 'Taste' Fructose, Hinting at Links to Diabetes 2Health News:Pancreas May 'Taste' Fructose, Hinting at Links to Diabetes 3Health News:Certain Cancer Drugs May Have Fatal Side Effects: Analysis 2Health News:Discovery predicts patient sensitivity to important drug target in deadly brain cancer 2Health News:Combined oral contraceptive pill helps painful periods 2Health News:Combined oral contraceptive pill helps painful periods 3Health News:Combined oral contraceptive pill helps painful periods 4Health News:Researchers examine consequences of non-intervention for infectious disease in African great apes 2Health News:Researchers examine consequences of non-intervention for infectious disease in African great apes 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: